For a typical adult requiring long‑term antidepressant therapy, how should antidepressants be ranked according to overall tolerability and ease of discontinuation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ranking Antidepressants by Tolerability and Ease of Discontinuation

For adults requiring long-term antidepressant therapy, escitalopram, citalopram, sertraline, and bupropion should be prioritized for their superior tolerability profiles, while fluoxetine offers the easiest discontinuation due to its long half-life, and paroxetine, fluvoxamine, and venlafaxine should be avoided due to high discontinuation syndrome risk.

Tolerability Rankings

Most Tolerable (Lowest Discontinuation Rates)

Tier 1 - Best Overall Tolerability:

  • Escitalopram: Consistently associated with fewer dropouts and lower adverse event rates 1
  • Citalopram: Minimal CYP450 interactions, lower propensity for drug-drug interactions, and favorable tolerability 2, 1
  • Sertraline: Lower discontinuation rates due to adverse events compared to other SSRIs 1
  • Agomelatine: Associated with fewer dropouts than placebo (OR 0.84) 3

Tier 2 - Good Tolerability:

  • Fluoxetine: Associated with fewer dropouts than placebo (OR 0.88) 1
  • Bupropion: Lower discontinuation rates, particularly when used for augmentation 4
  • Mirtazapine: Favorable tolerability profile 1
  • Vortioxetine: Reasonable tolerability in maintenance treatment 5

Least Tolerable (Highest Discontinuation Rates)

Avoid or Use with Caution:

  • Venlafaxine: 40% higher risk of discontinuation compared to SSRIs as a class 1
  • Duloxetine: 67% higher risk of discontinuation compared to SSRIs 1
  • Paroxetine: Higher rates of adverse effects, particularly in older adults; associated with increased suicidal thinking compared to other SSRIs 2, 1
  • Clomipramine: Worse than placebo for acceptability (OR 1.30) 3
  • Fluvoxamine: Higher dropout rates and greater potential for drug-drug interactions 2, 3

Discontinuation Syndrome Risk

Ease of Discontinuation Rankings

Easiest to Discontinue:

  1. Fluoxetine: Long half-life (longest among SSRIs) minimizes withdrawal symptoms; allows for natural tapering 2
  2. Escitalopram: Moderate half-life, lower withdrawal risk
  3. Citalopram: Similar profile to escitalopram

Most Difficult to Discontinue (High Withdrawal Risk):

  1. Paroxetine: Most strongly associated with discontinuation syndrome due to shortest half-life among SSRIs 2
  2. Fluvoxamine: Significant discontinuation syndrome risk 2
  3. Sertraline: Associated with discontinuation syndrome, though to a lesser extent than paroxetine 2
  4. Venlafaxine: SNRI with notable withdrawal symptoms

Critical Discontinuation Syndrome Features

Withdrawal symptoms include 2:

  • Dizziness, fatigue, lethargy, general malaise
  • Myalgias, chills, headaches
  • Nausea, vomiting, diarrhea
  • Insomnia, imbalance, vertigo
  • Sensory disturbances, paresthesias
  • Anxiety, irritability, agitation

These symptoms occur most commonly with:

  • Shorter-acting SSRIs (paroxetine > fluvoxamine > sertraline)
  • Abrupt discontinuation or missed doses
  • SNRIs (venlafaxine, duloxetine)

Practical Clinical Algorithm

Initial Selection Priority:

For typical adults:

  1. First choice: Escitalopram or sertraline (best balance of tolerability and efficacy)
  2. Second choice: Citalopram or fluoxetine
  3. For patients concerned about sexual side effects: Bupropion or mirtazapine
  4. For older adults (≥65 years): Escitalopram, sertraline, or citalopram 1

Avoid in older adults: Paroxetine and fluoxetine due to higher adverse effect rates 1

When Discontinuation is Anticipated:

If patient may need to stop treatment:

  • Best choice: Fluoxetine (self-tapering due to long half-life)
  • Acceptable: Escitalopram, citalopram
  • Avoid: Paroxetine, fluvoxamine, venlafaxine

Common Pitfalls to Avoid

  1. Rapid tapering: Most studies used 4-week or shorter tapers, which may be insufficient 6. Consider longer tapering periods (several months) to minimize withdrawal symptoms.

  2. Confusing withdrawal with relapse: Withdrawal symptoms (low mood, dizziness) can mimic depression relapse 6. This is a critical distinction that affects treatment decisions.

  3. Using paroxetine for long-term treatment: Despite its efficacy, paroxetine's high discontinuation syndrome risk and increased suicidal thinking make it a poor choice for maintenance therapy 2, 1.

  4. Overlooking drug interactions: Fluvoxamine has extensive CYP450 interactions (1A2, 2C19, 2C9, 3A4, 2D6), while citalopram/escitalopram have minimal interactions 2.

Important Nuances

About 63% of patients on second-generation antidepressants experience at least one adverse effect 1. Nausea and vomiting are the most common reasons for discontinuation overall.

Number needed to harm for discontinuation: 20-90 for SSRIs versus 4-30 for tricyclics 1, demonstrating SSRIs' superior tolerability.

SNRIs (venlafaxine, duloxetine) show slightly better efficacy than SSRIs but are associated with significantly higher rates of nausea, vomiting, and discontinuation 1. This trade-off should be carefully considered.

The evidence base has limitations: Most discontinuation studies used rapid tapers (≤4 weeks) and focused on patients with recurrent depression 6. True discontinuation rates and optimal tapering strategies for typical primary care patients remain uncertain.

References

2
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Related Questions

Can you analyze the urinalysis results?
What is the best oral hormone replacement therapy tablet for a generally healthy post‑menopausal woman with an intact uterus?
What full‑time spectacle prescription should be given for a patient with a refraction of +2.25 – 1.75 × 135 in the right eye (OD) and +2.50 – 1.25 × 125 in the left eye (OS), with no near addition (ADD 0.00 D)?
In a 41‑year‑old patient on long‑term hemodialysis who has daily frontal pressure headaches that awaken him at night and progressive tense swelling of both hands associated with high‑flow arteriovenous fistulas, what are the likely causes and the appropriate diagnostic and management steps?
What are the differential diagnoses for a patient with bilateral axillary erythema, scattered red maculopapular rash on the arms, erythema in the elbow flexures, and erythema behind the knees?
What are the DSM‑5 criteria for postpartum depression and is sertraline (Zoloft) safe for a breastfeeding mother?
What is the appropriate management of circulatory failure in a 30‑year‑old female with traumatic brain injury who requires norepinephrine infusion at 100 µg/min?
A patient began oral bioidentical hormone replacement therapy with progesterone 100 mg and estradiol 1 mg 16 days ago and experienced a brief, resolved dizziness spell; what is the appropriate management?
What is the diagnosis and recommended management for a boy kept in a sterile bubble due to severe combined immunodeficiency (SCID)?
What are the weight gain risks associated with Vraylar (cariprazine)?
In a patient with a junctional rhythm, is it safe to switch metoprolol to nebivolol (Bystolic)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question